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Abstract 
Exploration missions will present significant new challenges to crew health, including effects of variable gravity 
environments, limited communication with Earth-based personnel for diagnosis and consultation for medical events, 
limited resupply, and limited ability for crew return. Providing health care capabilities for exploration class missions 
will require system trades be performed to identify a minimum set of requirements and crosscutting capabilities, which 
can be used in design of exploration medical systems. Medical data, information, and knowledge collected during 
current space missions must be catalogued and put in formats that facilitate querying and analysis. These data are used 
to inform the medical research and development program through analysis of risk trade studies between medical care 
capabilities and system constraints such as mass, power, volume, and training. Medical capability as a quantifiable 
variable is proposed as a surrogate risk metric and explored for trade space analysis that can improve communication 
between the medical and engineering approaches to mission design. The resulting medical system design approach 
selected will inform NASA mission architecture, vehicle, and subsystem design for the next generation of spacecraft. 
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Health (LSAH), Integrated Medical Model (IMM), 
International Space Station (ISS), Life Sciences Data 
Archive (LSDA), Exploration Medical Condition List 
(EMCL), Medical Optimization Network for Space 
Telemedicine Resources (MONSTR), subject matter 
expert (SME), quality time lost (QTL), loss of crew life 
(LOCL), solar particle events (SPE), extravehicular 
activity (EVA), Exploration Medical Capability 
(ExMC), Design Reference Mission (DRM), 
evacuation of the space station (EVAC)  
 
1. Introduction 
 Overview 
Exploration class missions will present significant 
new challenges to crew health that will be unique from 
those experienced during missions conducted in low 
earth orbit (LEO). Crew will need to traverse the 
terrain of lunar, asteroid, or planetary surfaces during 
exploration and function in a variety of reduced gravity 
environments [1]. Limited communication with Earth-
based personnel for the purpose of medical event 
consultation creates additional challenges. New mental 
and behavioural health needs will need to be carefully 
considered. Providing health care capabilities for 
exploration class missions will necessitate the 
definition of new medical requirements and 
development of technologies to ensure the safety and 
success of exploration missions. 
“Given that medical capabilities will be limited 
during human exploration missions, there is a 
possibility that in-flight medical events will lead to 
undesirable health and mission outcomes.” [2] 
Planning for exploration requires understanding of 
the space flight environment, tasks that will be required 
to out carry a mission, and the potential effects on 
humans. Current and future medical data, information, 
and knowledge must be aggregated to facilitate 
querying and analysis. This data and information must 
be used to inform the medical research and 
development program through analysis of the trade-
offs between medical care capabilities and system 
constraints such as mass, power, volume, and training. 
Medical technology is a rapidly evolving field. The 
likelihood is low that a stable set of requirements can 
be established that exploits current technologies to 
provide a capable medical system for exploration 
missions not slated to fly for ten years. In order to 
address this reality, an incremental and iterative 
approach to system design is envisioned to incorporate 
the inevitable growth of technology. Additionally, 
since the human system is complex and effects of the 
space environment are not completely known, any 
system proposed should maximize flexibility to enable 
a care provider to address conditions that were not 
considered in the initial design. 
 
https://ntrs.nasa.gov/search.jsp?R=20160011168 2019-08-29T16:39:08+00:00Z
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1.2 Background  
National Aeronautics and Space Administration 
(NASA) was prompted in 2001 to improve the 
integration of the vehicle and human systems through 
a very intentional and evidence based design of 
medical systems to support human spaceflight during 
exploration missions [3]. This has affected the 
structure of Space Medicine Operations as well as the 
Human Research Program (HRP) in how they both 
approach the problem of exploration medical needs in 
the context of a Mars mission. NASA has responded 
through both the implementation of an occupational 
health model that incorporates occupational 
surveillance principles and the structure and close tie 
between the elements of HRP to occupational 
surveillance. 
The occupational surveillance work enables studies 
of astronaut health pre-flight, in-flight, and post-flight 
capture incidences of medical conditions during space 
missions. This enables ongoing compilation and 
tracking of common and high risk conditions that are 
likely to require medical attention during long-duration 
exploration missions. The NASA Lifetime 
Surveillance of Astronaut Health (LSAH) [4] collects 
data on astronaut medical care and workplace 
exposures, especially those occurring in the training 
and space flight environments, and conducts 
operational and health care analyses to look for trends 
in exposure and health outcomes. This data is used to 
feed quantitative risk tools described below including 
the Integrated Medical Model (IMM). NASA’s Life 
Sciences Data Archive (LSDA) [5] also includes data 
from human subjects derived from both past and 
current space flight, as well as data from analogue 
studies. Several publications provide an overview of 
in-flight medical condition incidences [6-8]. Table 1 
shows the occurrences of medical conditions 
experienced by NASA astronauts during previous 
space missions. The data obtained from LSAH records 
for medical conditions that occurred among United 
States astronauts during the Space Shuttle Program 
(through STS-114 in 2005), Mir, and International 
Space Station (ISS) (through Expedition 13 in 2006) 
missions are used to inform modelling estimates that 
are applied to current operations and future exploration 
missions. Data included from Apollo and Skylab 
missions are based on publications [9].  
Several of these conditions are not high-risk or 
emergency in nature, requiring a relatively low level 
of treatment resources such as medication and crew 
medical officer input. Non-emergency conditions that 
have occurred during space missions include: 
dermatological, musculoskeletal, cardiovascular, and 
mild psychiatric conditions, as well as minor trauma 
and burns. Of greater concern, particularly for longer 
and more remote exploration missions, is the potential 
for more serious or life-threatening medical conditions 
during a space flight mission. Both benign and more 
serious cardiac arrhythmias (supraventricular and 
ventricular tachycardia) have been reported during 
previous Mir, Skylab, and Apollo missions [10]. In 
cases that are emergent the option of evacuation of 
crews to provide the highest levels of medical care has 
been available to all human spaceflight missions to 
date. This is an option that may be unavailable on 
future long-duration exploration missions. 
Historically dental [11,12] and urological emergencies  
[13, 14] have been documented among astronauts and 
behavioural and mental health episodes have been 
successfully managed with near real-time 
psychological support during LEO missions [15]. 
Issues like these will require autonomous handling 
during exploration missions and provide a unique 
forward challenges. 
 
1.3 Medical System Design Context 
Current architectures for exploration call for long 
duration missions of 1-3 years [2]. These missions will 
face challenges not faced by prior programs. 
Uncertainties will be higher in the new environments, 
and resources will generally be more constrained.  
The duration of these future missions exceed 
current spaceflight experience base. Current ISS 
operations baseline 6-month duration increments with 
half the crew rotating in and out approximately every 
three months. Worldwide, six Astronauts/Cosmonauts 
have exceed 1-year in microgravity, with the longest 
duration being 437 days. The current record for a 
female astronaut is 199 days in space [16]. The 
expectation for exploration missions is mixed gender 
crews. This limited evidence base results in higher 
Table 1. Number of occurrences of medical conditions 
that have affected NASA astronauts during previous 
space missions [9]. 
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uncertainties for system design drivers. The medical 
system will need to address this uncertainty by 
providing additional flexibility to respond to 
unplanned events. 
Because of the distances and mechanics involved, 
deep space missions will have a set of resource 
constraints which are not encountered in LEO missions 
[1]. Cis-lunar missions will require a minimum of 3 
days for medical evacuation. Mars and other 
destinations will not have a capability for medical 
evacuation. Mars missions cannot expect resupply 
although some prepositioning of resources may be 
available. There will be periods of limited 
communications and extended transit times. With an 
expected 22-minute delay on one-way 
communications during some mission phases, a Mars 
medical system must be designed for considerable 
more autonomy than previous medical systems. 
Finally, due to the low margins available on these 
missions, we can expect increasing scrutiny and 
competition for resources across mission systems.  
We can reasonably expect that future information 
processing and data handling capabilities will continue 
to expand. Additionally, lower mass and less power 
consuming medical technologies will become 
increasingly available as they are driven by a 
competitive marketplace. 
 
2. Approach 
2.1 Risk Reduction Strategy 
“In this regard, although research in most fields 
may continue ad infinitum, the Bioastronautics 
Roadmap should attempt to identify what is good 
enough” for the launch of a given category of mission. 
Researchers in virtually all fields are reluctant to 
declare total success, since this would be tantamount 
to forfeiting future funding. In the conduct of 
exploration, leaders cannot wait until every detail is 
resolved definitively, but only until the collective risk 
is mitigated adequately or otherwise reduced to permit 
a high enough level of optimism to justify mission 
initiation.” [17]  
The question in defining a medical system is how 
can we leverage improving capability to minimize 
risk within the known constraints? The resource 
limitations of exploration missions require proposed 
medical solutions that include consideration of mission 
constraints and architecture capabilities in medical risk 
assessments. 
To address the problem of providing a medical 
system for extended exploration missions, a suite of 
medical capabilities will need be identified, developed, 
and integrated. Risk metrics need to be identified, and 
risk models will be developed to quantify outcomes for 
missions based on the proposed capabilities. Using 
these models, design requirements can be identified 
that will reduce the system risk. 
The generalized elements of a system level 
approach to medical risk include the following 
considerations: 
1. Development of risk metrics. 
2. Development of assessment tools to allow 
quantification of risk. 
3. Identification of risk drivers or influential 
capabilities. 
Identification of risk metrics allows prioritization 
of risk mitigation approaches within the medical 
system, which will drive the solution space available to 
influence these metrics. Typical risk metrics used for 
spaceflight at the program level include loss of crew 
and loss of mission. For medical system optimization, 
these metrics do not provide the level of discrimination 
required for some systems trades. In particular, a 
medical system is judged by its ability to provide a 
crew fit for duty when called which will require the 
ability for general prevention, screening, diagnosis, 
and treatment. This suggests the need for crew 
performance metrics. Inclusive of this is the need for 
long-term treatment, as manifested by rehabilitation 
and palliative care. One other difficulty in determining 
medical risk metrics is a reticence to establish a 
baseline risk acceptance criteria in the face of rapidly 
evolving capability. We do not expect definitive risk 
acceptance levels to be established until an exploration 
mission has been baselined.  
“A sustained human exploration program beyond 
LEO, despite all reasonable attention paid to safety, 
will almost inevitably lead to multiple losses of vehicles 
and crews over the long term. For each step along the 
pathway, it will be important for NASA leadership and 
other stakeholders to discuss risk honestly and to 
establish acceptable levels of risk to missions and 
crews for deep-space missions. At the Agency level, the 
risk discussion will be more detailed and will use 
relative or probabilistic levels to define the risk 
threshold, inform the design, and set priorities.” [18] 
With this constraint in mind, we chose to compare 
exploration medical capability against a measurable 
baseline – the terrestrial standard of care. By 
comparing capability against a common standard, 
progress towards reducing the medical risk could be 
measured. NASA currently estimates risk in terms of 
likelihood and consequence. In the medical domain the 
likelihood of any particular event can be estimated 
from either known spaceflight events in the past or 
from appropriately generalizable populations in 
terrestrial medicine. Neither of these are perfect, but 
given the lack of data on medical events in the 
exploration domain beyond LEO, these are the best 
that can be expected at this time. The consequence side 
of medical risk is more difficult to quantify. Medical 
67th International Astronautical Congress (IAC), Guadalajara, Mexico, 26-30 September 2016.  
 
IAC-16,E3,6,11,x35540   Page 4 of 11 
consequence is assessed through decrements in crew 
performance or morbidity but cannot be well measured 
in that definition.  
“Consequence can be a mission level effect or an 
individual crew morbidity or mortality. In both these 
approaches, consequence requires a means of 
assessing the expected effectiveness of a medical 
capability in mitigating the effects of a medical 
condition occurring. It is impossible to predict the 
effectiveness of all possible medical treatments given 
an assumed resource set. However it is possible to 
measure a proposed resource set against a gold 
standard. If the gold standard resource set is defined 
as resources available to a US based tertiary care 
hospital, then the preventive, diagnostic, treatment, 
and rehabilitation capabilities of a proposed medical 
system can be measured against that gold standard as 
a measure of medical readiness rather than 
predictable effectiveness. Since even the relatively 
unlimited capability of a tertiary care hospital cannot 
provide perfect outcomes, it is considered that medical 
readiness as measured by capability provision is a 
viable risk metric.” [19]  
By using medical capability as a demonstration of 
medical readiness, a metric for consequence can be 
tabulated and calculated. At the time of program 
implementation a decision regarding required 
capability can then be made.  
The Human Research Program has developed 
several assessment risk tools to assist in quantifying 
risk. The Exploration Medical Condition List (EMCL) 
provides a list of conditions of concern for exploration 
missions. The IMM uses historical information to 
estimate medical event occurrence. The Medical 
Optimization Network for Space Telemedicine 
Resources (MONSTR) is designed to catalogue the 
current terrestrial standard of care as a documented 
baseline of human health care. 
The EMCL provides a framework to organize the 
results of medical systems needs analyses. IMM can be 
considered as a provider of incident rates for a medical 
event. MONSTR can be considered as the source for 
resource requirements for medical events. By 
integrating the resource calls across all conditions, an 
initial set of influential medical capabilities can be 
defined.  
 
2.2 Risk Measures and Tools 
 
2.2.1 Exploration Medical Conditions List 
Early in the planning for exploration missions, the 
need for a list of medical conditions of interest was 
identified. JSC-65722 EMCL was created to address 
this need drawing on spaceflight experience to 
document the set of medical conditions of primary 
interest for medical system development [20]. 
“The purpose of the list is to serve as a foundation 
for identifying medical conditions of interest which 
could affect a crewmember during a given mission 
profile, which of those conditions would be of concern 
and require treatment, and for which conditions a gap 
in knowledge or technology development exists. This 
information will be used to focus research efforts and 
technology development.”  
The EMCL (Table 2) is applicable to medical 
conditions that could occur in several exploration 
mission profiles. The intent of this list is to identify 
conditions that occur as a consequence of human space 
flight and human habitation of space, in addition to 
injuries that result from hardware or vehicle failure. A 
condition was listed as “not addressed” if it is highly 
unlikely to occur, is expected to be engineered out, or 
limitations in medical training/hardware/consumables 
preclude its treatment. 
The EMCL is expected to be an evolving document 
as our evidence base for spaceflight grows, it will be 
updated accordingly. 
 
2.3 Integrated Medical Model 
For quantitative evidence based decision support, 
the IMM combines organizational knowledge, 
published literature, and in-flight medical event data in 
a statistical modeling tool to produce simulations of 
medical scenarios that may impact astronaut health 
during a mission [21]. The output of IMM provides 
comparative estimates of in-flight risk and medical 
resource utilization based on specifications of mission 
parameters, including crew profiles and mission length 
and availability of medical resource options. 
Currently, the medical condition input data 
represents 100 medical conditions that have occurred 
in space or concern the space medical community. 
Baselined to the ISS, space flight health studies 
provide the data for conditions that have occurred 
during space flight (Table 1). Analog studies, general 
population data, SME opinion, and data derived from 
specifically constructed Bayesian statistical analyses 
serves to provide incidence estimates for conditions 
that have yet to occur, or have occurred infrequently. 
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Table 2. EMCL Medical Conditions 
 
Abdominal Injury Dental – Filling 
Replacement 
Indigestion Seizure 
Abdominal Wall 
Hernia 
Dental - Crown 
Replacement 
Insomnia (Early/Late) Sepsis 
Acute Arthritis Dental - Exposed 
Pulp/Pulpitis 
Intra-Abdominal Infection 
(Diverticulitis, Appendicitis, Other) 
Shoulder Dislocation 
Allergic Reaction 
(Mild to Moderate) 
Dental - Abscess Lumbar Spine Fracture Sinusitis 
Altitude Sickness Dental - Avulsion/ Tooth 
Loss 
Malignancy Skin Abrasion 
Anaphylaxis Depression Medication Overdose/Adverse 
Reaction 
Skin Laceration 
Anxiety Diarrhea Mouth Ulcer (aphthous ulcer; Herpes 
Simplex Virus – cold sore) 
Skin Rash 
Back Injury Dysfunctional Uterine 
Bleeding 
Nasal Congestion (Space Adaptation) Small Bowel Obstruction 
Back Pain  
(Space Adaptation) 
Elbow Dislocation Nausea/Vomiting Smoke Inhalation 
Barotrauma  
(Ear/Sinus Block) 
Eye Abrasion  
(Foreign Body) 
Neck Injury Space Motion Sickness 
(Space Adaptation) 
Behavioral Emergency Eye Chemical Burn Nephrolithiasis Extremity Sprains/Strains 
Burns Eye Corneal Ulcer Neurogenic Shock Stroke 
Cardiogenic Shock Eye Infection Nosebleed (Space Adaptation) Sudden Cardiac Arrest 
Cellulitis Eye Penetration  
(Foreign Body) 
Osteoporosis Surgical Treatment 
Chest 
Injury/Pneumothorax 
Finger Dislocation Otitis Externa Toxic Exposure 
Chest Pain/Angina Fingernail Delamination 
(EVA) 
Otitis Media Upper Extremity Fracture 
Choking/Obstructed 
Airway 
Glaucoma – Acute Palliative Treatment Urinary Incontinence  
(Space Adaptation) 
Compartment 
Syndrome 
Head Injury Paresthesias/Hot Spots (EVA) Urinary Retention  
(Space Adaptation) 
Constipation  
(Space Adaptation) 
Headache (CO2, Space 
Adaptation, Other) 
Pharyngitis Urinary Tract Infection 
De Novo Cardiac 
Arrhythmia 
Hemorrhoids Prostatitis Vaginal Yeast Infection 
De Novo Hypertension Herpes Zoster 
Reactivation 
Radiation Sickness Visual 
Impairment/Intracranial 
Hypertension 
Decompression 
Sickness 
Hip/Lower Extremity 
Fracture 
Respiratory Infection  
Dental - Caries Hypovolemic Shock Retinal Detachment  
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The IMM uses the input data to produce estimates 
of crew health, resource utilization, and mission 
outcomes. IMM estimation of the outcome of a given 
medical condition requires consideration of a number 
of factors, including the severity at presentation, 
defined as either the best or the worst-case scenario. 
IMM expresses the models findings in the form of 
output measures such as the quality time lost (QTL) to 
an astronaut due to medical events, the probability of 
the need to consider evacuation of the space station 
(EVAC), and loss of crew life (LOCL) resulting from 
inability to sufficiently address a medical event. Of 
note, the model accounts for the degree of functional 
impairment of the crew medical officer(s) due to the 
particular medical condition. 
IMM achieves these estimates through intelligent 
implementation of Monte Carlo probabilistic 
techniques, implementing a randomly generated 
mission with each model trial and accounting for the 
medical condition treatment and clinical outcomes 
based on resource availability. An IMM trial consists 
of applying the medical condition probability profiles 
and specific mission scenario variables, such as 
crewmember attributes, extravehicular activities and 
mission duration to generate the mission medical event 
and outcome events. The IMM also accounts for events 
unique to the spaceflight environment, such as solar 
particle events (SPE) and extravehicular activities 
(EVAs) that may lead to the presentation of associated 
medical conditions. Primary outcomes describing the 
impact of medical events on the missions are described 
in terms of the QTL, probability of EVAC, and 
probability of LOCL. Subsequent to the probabilistic 
modeling aspects of IMM, IMM optimization routines 
allow for trades between medical resource mass and 
volume and the one of the IMM risk metrics [22], 
providing an initial, evidence based assessment of the 
mission medical resources for mission designers and 
decisions makers. 
 
2.4 Medical Optimization Network for Space 
Telemedicine Resources 
The ability to evaluate the resource trade space for 
prevention, screening, diagnosis, and treatment of 
medical conditions is essential during the development 
of an exploration mission medical system. MONSTR 
is a decision support system that is being designed to 
provide users the ability to assign resources required 
for medical intervention and relative importance to 
those resources. The MONSTR is a data repository to 
catalogue treatment resources required for conditions 
identified in the EMCL. Tangible items such as 
equipment, medication, and medical procedures 
required to respond to a condition are identified, along 
with non-tangible items such as the clinical skillsets 
required to execute the procedure. Figure 1 shows an 
example of the data types and categorizations that are 
expected in MONSTR. Because of the complexity of 
the data structure, it is important to capture a complete 
data array and retain those relationships to the 
condition. 
MONSTR is a pilot research project currently designed 
to show whether the specific approach of this type of 
relational database can provide value to mission 
planners who have a need to explore the medical 
capabilities trade space. MONSTR is populated with 
resources that are considered typical for a health care 
facility in a first world nation to be used as the 
“Terrestrial Standard of Care”. By populating each 
condition with nested resources required to implement 
a diagnosis or a treatment for that condition retains the 
relationship between the full set of resources needed to 
intervene on a potentially ill crew member. The project 
and its outcomes are described briefly here. A follow 
up version is currently being researched to improve 
upon lessons learned. Data shown here should be 
considered notional and representative of the potential 
of the tool but not a final product.  
 
Figure 1. Typical MONSTR Data and Criticality 
 
The prototype version of MONSTR consists of a 
SQL database that interfaces with business analytics 
software for data visualizations/reporting. It is 
currently populated with information provided by six 
board certified physicians in Aerospace Medicine, 
Emergency Medicine, Family Medicine, Internal 
Medicine, and Physical Medicine and Rehabilitation. 
Condition Use Case Resource Type Resource Criticality
Vital Signs 3
Physical Exam - Abdominal 3
Physical Exam - Trauma Survey 2
Ultrasound - AC 2
CT - Torso 3
BMP 2
CBC 3
LFT 2
Lactate 3
Lipase 1
UA 3
IV Access - Minor 2
IV Fluids 1
Monitoring - Standard 2
Medication Analgesics 3
IV Access - Minor 3
IV Access - Major 3
IV Fluids 2
Blood Products 3
Monitoring - ICU 3
Advanced Airway 3
Palliative Care 1
Surgery Surgery - Trauma 3
Antibiotics 1
Analgesics 3
Antifibrinolytics 2
Abdominal 
Injury
Diagnosis
Treatment 
(Best Case)
Treatment 
(Worst Case)
Procedure
Imaging
Lab
Procedure
Lab
Medication
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Definitions of the medical condition and their best and 
worst case scenarios are taken from the IMM 
definitions [21]. Rankings of each of the resources with 
regards to ‘medical criticality’ are given by consensus 
among the physicians informing the model. Medical 
Criticality in the prototype version is on a scale from 
zero to three. Zero is not applicable, three is a resource 
critical to the intervention, one is a resource that would 
be nice to have but is not critical, and two is anything 
in-between a one and a three. Figure 1 shows an early 
breakdown of this from a prototype database.  
Deconstruction of medical resources required for a 
given intervention allows development of relative 
weighting for those resources not only by medical 
criticality but also by the probability of occurrence for 
any given condition. Probability of occurrence is 
calculated by the IMM and easily exported for each 
condition to the MONSTR database to further weigh 
the estimated relative ‘value’ of each resource. This 
approach attempts to create a ‘level playing field’ by 
which the relative utility of resources can be compared. 
For example, mission planning decisions that may 
hinge on deciding whether to include an ultrasound, an 
Automatic External Defibrillator, or an increased 
volume of high use medications such as Ibuprofen 
currently have no quantitative method for weighing the 
‘value’ of these items to a specific mission scenario. 
The relative value is some combination of how often 
conditions are expected to occur that might need the 
resource as well as the utility of the resource in 
different scenarios when called on. This approach is 
directed toward providing a ‘ballpark estimate’ of 
these values to mission planners and SME who then 
will need to exercise discretion in interpreting the 
results applicability. Expert evaluation is critical as 
MONSTR is populated with information from 
terrestrial medical experience and interpretation is for 
the context of spaceflight. For example, if an MRI were 
to be found highly valuable, that particular output 
could be downgraded by an SME who understands the 
low likelihood of implementing that type of technology 
in spaceflight. On the other hand, if a capability like X-
ray shows high value, then the  Exploration Medical 
Capability (ExMC) element may elect to invest in 
research that would seek to minimize mass and 
optimize integration capability with a medical system 
to determine if it is a viable exploration medical 
capability. This highlights the value of a quantitative 
approach to capability and resource ‘value’ in 
informing an applied research pathway. 
  
3. Results 
Initial analysis of from these two tools will be 
facilitated through the use of Centrifuge Systems 
(McLean, VA, USA) and Tableau® (Seattle, WA, 
USA) visualization software. These tools are being 
used to integrate the application of resources across the 
medical condition space prioritized by resource call 
rate and criticality. 
The IMM outputs provide incidence rate estimates 
for medical events per mission. MONSTR catalogues 
the resource requirements for each condition in an 
idealized Terrestrial Standard. MONSTR also provides 
a criticality weighting to the resource which provides 
an initial assessment of the importance of a resource to 
a treatment plan. Total resource calls per mission can 
be calculated by integrating the resource calls across 
all events for a mission. Utilizing the criticality 
estimates to modify the weighting of each resource call 
can further modify the estimate of call rate to better 
reflect the relative importance of a particular resource 
to the mission of interest. 
Multiple visualizations may be performed to 
identify relationships to suites of treatment capability. 
Figure 2 shows a broad spectrum of potential output 
formats available through the use of Centrifuge. This 
one sample can be used to illustrate the need for 
software tools to retain multiple data relationships 
which may be displayed in multiple ways depending 
on the analytical need. In this case multiple graphics, 
numbers, and color provide insight into a highly 
networked data set. 
Once the dataset has been accumulated, specific 
questions can be asked and subsequently visualized. 
Figure 3 shows a particular slice of the dataset, the 
relative importance of laboratory assays that might be 
called in a Mars design reference mission (DRM). In 
this example, the resource weighted criticality, total of 
resource calls adjusted for incidence (blue), versus 
unweighted criticality, total of calls (grey) shows the 
importance of considering incidence when assessing 
the importance of a given resource for a mission.  
 Unweighted criticality is defined as the physician’s 
estimate of medical criticality of a particular resource 
to a particular condition summed over all conditions. 
Weighted criticality is the unweighted criticality 
multiplied by the probability of occurrence. This 
weighting preference is utilized in the pilot 
demonstration and is not the final algorithm for 
interpretation. However, it does enable an assessment 
of the utility of this approach.  
Figure 3 shows laboratory assays that would be 
called upon in a terrestrial medical case are weighted 
according to the above formulas. This highlights the 
critical evaluation of these starting results by SME’s 
for interpretation. For example, the top three laboratory 
panels include complete blood count, basic metabolic 
panel, and a urinalysis. These likely have high value in 
helping with diagnosis in both domains. However, 
laboratories further down the list might be pared from 
consideration This provides a starting point to 
understand how much value these particular resources 
have in the terrestrial environment when weighted by 
how likely they are to occur in the spaceflight 
environment. 
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Alternately, we can probe the dataset for categories 
of resource calls. Figure 4 is a visualization of this 
question to graphically show the resource type relative 
rankings. This could form the basis for the first step in 
a Pareto analysis. 
The category definitions are not final, but give 
insight into the relative value of different treatment 
needs. The largest category value is medications here, 
which is not unexpected in the context of space 
medicine needs. However, the calls for major and 
minor surgery may be more insightful. Major surgery 
is defined as a tissue-cutting intervention that would 
require an operating room to implement. Minor 
surgery is defined as a tissue cutting intervention that 
can be performed in an emergency department in 
completeness. When visualized for relative value the 
need for major surgical capabilities applies mostly to 
worst case scenarios in medical situations. Not shown 
here are the sheer volume of resources required to 
implement a major surgery. In that context this could 
inform decisions on how much capability is warranted 
in the face of significant resource limitations.  
It is critical to recognize the model limitations and 
output must be interpreted by SMEs, but this approach 
Figure 3. Relative importance of laboratory analyses 
for Mars DRM 
Figure 2. Sample MONSTR Outputs 
 
67th International Astronautical Congress (IAC), Guadalajara, Mexico, 26-30 September 2016.  
 
IAC-16,E3,6,11,x35540   Page 9 of 11 
allows for the organization of a complex data set to 
facilitate understanding the relationships across the 
entire set of possible risk mitigations. Visualization is 
an approach that can allow intuitive insight, which may 
then be subjected to more rigorous analysis [23].  
 
4. Discussion and Future Work 
Categorization and quantification of medical 
capability is a promising approach to measuring 
progress in medical risk reduction. The success of the 
approach will be dependent on establishing an 
accepted risk framework and developing validated data 
sources for decision support. 
During the initial assessment of results, it became 
clear that further work needs to be done in resource 
weighting and integrating across the event space. In 
particular, the relative weight of resources used for low 
probability/high impact conditions against high 
probability/low impact conditions can affect results. A 
specific example would be the relative importance of 
Sepsis treatments, which are highly unlikely to be used, 
but absence will result in death vs accommodation of 
topical ointments, which a nearly certain to be used and 
depletion will result in crew discomfort and possibly 
significant reduction in crew/mission performance 
measures. These risk trades are not unique to the 
medical system; however, this approach has 
highlighted some of these trades early in the design 
process. 
Future work in this area includes developing an 
architecture of tools for systems evaluations. A 
notional representation is shown in Figure 5 Medical 
system design evaluations must include the risk 
metrics and clinical value of system capabilities as 
described in this paper, however, additional aspects 
must be included in more mature and comprehensive 
evaluations over time. For example, medical system 
functional and performance requirements will be 
derived from a concept of operations currently in work. 
Medical system design options must then be assessed 
for their ability to meet these requirements. In addition, 
as communication with mission operational and 
vehicle design engineering SME’s increases, 
additional interface requirements and constraints will 
be identified for further design option evaluation. 
Feasibility of the medical system volume and layout 
within a vehicle or habitat must also be considered. The 
suite of tools to accomplish these evaluations will be 
architected to support medical system evaluations that 
respond to evolving requirements and technologies as 
exploration mission scenarios are being defined. 
Finally, an unexploited area for work alluded to in 
this paper is stronger analysis of medical system design 
on health and performance of crew. Results from this 
analysis can be used to drive architecture design to 
reduce crew medical risk caused by the mission 
systems. 
 
5. Conclusions 
The complexity of the medical decision space is 
such that a rote approach to system design through 
prioritization is doomed to failure. At best, these tools 
can be used to organize a large networked data set to 
support decision making and understand the 
implications of design choices. 
For the exploration medical systems, a requirement 
for medical autonomy will become a driving factor as 
time to definitive care increases. Considerations 
around autonomy and medical system design are well 
described in A Risk Reduction Strategy for the Human 
Exploration of Space [17].  
“Both the biological and the operational research 
issues are aimed not at fundamental science, but at 
support of the specific health care delivery issues that 
are focused on crew health and mission success. What 
to treat? What not to treat? What to take in the 
vehicle’s medical supply manifest?... limitations 
imposed by upload volume and mass may preclude the 
availability of many techniques and impose a limited 
selection of options based on risk assessment and 
logistics.” 
The National Academy of Sciences Committee on 
Aerospace Medicine and the Medicine of Extreme 
Environments recommended [17]: 
“The committee recommends that a system be 
developed for quantitatively evaluating the mental and 
physical health risks that could affect mission success 
and crew health and that priorities for countermeasure 
development (i.e., definitive treatment vs. palliation) 
be established for the most likely conditions to be 
encountered during each reference mission. A panel of 
outstanding medical clinicians should be used to assist 
NASA medical operations staff in characterizing the 
likelihood, importance, and “treatability” of each 
condition.” 
The approach describes nascent steps towards 
building a quantitative approach to medical system 
Figure 4. Relative importance of resource types for 
Mars DRM 
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design requirement identification and trade space 
evaluations that will guide research investments. 
 
 
 
 
 
 
Figure 5 Notional System Evaluation Flow/Tools 
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